诱导多能干细胞与心脏再生

doi:10.3969/j.issn.1007-2861.2016.04.001

摘要/Abstract

摘要：

诱导多能干细胞(induced pluripotent stem cells, iPSCs)研究的快速发展为心血管转化医学研究领域提供了新的策略. 诱导多能干细胞不仅具有与胚胎干细胞类似的多能性, 且巧妙地回避了胚胎干细胞面临的伦理学问题和免疫排斥反应. 心肌细胞等成体心血管细胞在发生心血管疾病后增殖能力有限, 而iPSCs 来源的心血管细胞在心脏再生治疗中颇具应用前景,是理想的细胞来源, 因此在基础医学和转化医学研究领域受到广泛关注. 就iPSCs 的发展过程及其在心脏再生中的应用作一综述, 并探讨目前iPSCs 在心脏再生临床转化中亟待解决的问题.

关键词: , , , 心脏再生 , 诱导多能干细胞 , 重编程, 转化医学

Abstract:

Induced pluripotent stem cells (iPSCs) have emerged as a novel tool for cell therapy for cardiovascular diseases. iPSCs are functionally similar to embryonic stem cells (ESCs) while avoiding ethical issues and immune rejection. Given limited regenerative ability of human heart following cardiovascular diseases cardiovascular cells derived from iPSCs have been considered as a promising cell source in cardiovascular regenerative therapy. This paper summarizes and discusses the iPSCs technology and its potential regenerative applications in cardiac regeneration.

Key words: cardiac regeneration , reprogramming, translational medicine , induced pluripotent stem cell (iPSCs)

胡士军1,2, 虞游1,2, 方星1,2, 雷伟1,2, 赵振奥1,2. 诱导多能干细胞与心脏再生[J]. 上海大学学报(自然科学版), 2016, 22(3): 285-292.

HU Shijun1,2, YU You1,2, FANG Xing1,2, LEI Wei1,2, ZHAO Zhen’ao1,2. Induced pluripotent stem cells in cardiac regeneration[J]. Journal of Shanghai University（Natural Science Edition）, 2016, 22(3): 285-292.

参考文献

[1] Mozaffarian D, Benjamin E J, Go A S, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association [J]. Circulation, 2016, 133: e38-e360.

[2] Broughton K M, Sussman M A. Empowering adult stem cells for myocardial regeneration V2.0: success in small steps [J]. Circulation Research, 2016, 118: 867-880.
[3] Tabar V, Studer L. Pluripotent stem cells in regenerative medicine: challenges and recent progress [J]. Nature Reviews Genetics, 2014, 15: 82-92.
[4] Yamanaka S. Induced pluripotent stem cells: past, present, and future [J]. Cell Stem Cell, 2012, 10: 678-684.
[5] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors [J]. Cell, 2006, 126: 663-676.
[6] Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors [J]. Cell, 2007, 131: 861-872.
[7] Yu J, Vodyanik M A, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells [J]. Science, 2007, 318: 1917-1920.
[8] Zhao X Y, Li W, L¨u Z, et al. Ips cells produce viable mice through tetraploid complementation[J]. Nature, 2009, 461: 86-90.
[9] Kang L, Wang J, Zhang Y, et al. Ips cells can support full-term development of tetraploid blastocyst-complemented embryos [J]. Cell Stem Cell, 2009, 5: 135-138.
[10] Harding J, Roberts R M, Mirochnitchenko O. Large animal models for stem cell therapy [J]. Stem Cell Research & Therapy, 2013, 4: 23.
[11] Hochedlinger K, Jaenisch R. Induced pluripotency and epigenetic reprogramming [J]. Cold Spring Harb Perspect Bio, 2015, 7(12): a019448.
[12] Hou P, Li Y, Zhang X, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds [J]. Science, 2013, 341: 651-654.
[13] Raab S, Klingenstein M, Liebau S, et al. A comparative view on human somatic cell sources for ipsc generation [J]. Stem Cells International, 2014, 2014: 768391.
[14] Dubois N C, Craft A M, Sharma P, et al. Sirpa is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells [J]. Nature Biotechnology, 2011, 29: 1011-1018.
[15] Laflamme M A, Chen K Y, Naumova A V, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts[J]. Nature
Biotechnology, 2007, 25: 1015-1024.
[16] Burridge P W, Matsa E, Shukla P, et al. Chemically defined generation of human cardiomyocytes[J]. Nature Methods, 2014, 11: 855-860.
[17] Lian X, Bao X, Zilberter M, et al. Chemically defined, albumin-free human cardiomyocyte generation [J]. Nature Methods, 2015, 12: 595-596.
[18] Tohyama S, Hattori F, Sano M, et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes [J]. Cell Stem Cell, 2013, 12: 127-137.
[19] Orlova V V, Van Den Hil F E, Petrus-Reurer S, et al. Generation, expansion and functional analysis of endothelial cells and pericytes derived from human pluripotent stem cells [J]. Nature Protocols, 2014, 9: 1514-1531.

[20] Hu S, Wilson K D, Ghosh Z, et al. Microrna-302 increases reprogramming efficiency via repression of nr2f2 [J]. Stem Cells, 2013, 31: 259-268.
[21] Li Z, Hu S, Ghosh Z, et al. Functional characterization and expression profiling of human induced pluripotent stem cell- and embryonic stem cell-derived endothelial cells [J]. Stem Cells and Development, 2011, 20: 1701-1710.
[22] Marchand M, Anderson E K, Phadnis S M, et al. Concurrent generation of functional smooth muscle and endothelial cells via a vascular progenitor [J]. Stem Cells Translational Medicine, 2014, 3: 91-97.
[23] Gu M, Mordwinkin N M, Kooreman N G, et al. Pravastatin reverses obesity-induced dysfunction of induced pluripotent stem cell-derived endothelial cells via a nitric oxide-dependent mechanism [J]. European Heart Journal, 2015, 36: 806-816.
[24] Uygur A, Lee R T. Mechanisms of cardiac regeneration [J]. Developmental Cell, 2016, 36: 362-374.
[25] Nelson T J, Martinez-Fernandez A, Yamada S, et al. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells [J]. Circulation, 2009, 120: 408-416.
[26] Mauritz C, Martens A, Rojas S V, et al. Induced pluripotent stem cell (ipsc)-derived flk-1 progenitor cells engraft, differentiate, and improve heart function in a mouse model of acute
myocardial infarction [J]. European Heart Journal, 2011, 32: 2634-2641.
[27] Kawamura M, Miyagawa S, Miki K, et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model [J]. Circulation, 2012, 126: S29-S37.
[28] Funakoshi S, Miki K, Takaki T, et al. Enhanced engraftment, proliferation, and therapeutic potential in heart using optimized human ipsc-derived cardiomyocytes [J]. Scientific Reports, 2016, 6: 19111.
[29] Gu M, Nguyen P K, Lee A S, et al. Microfluidic single-cell analysis shows that porcine induced pluripotent stem cell-derived endothelial cells improve myocardial function by
paracrine activation [J]. Circulation Research, 2012, 111: 882-893.
[30] Xiong Q, Ye L, Zhang P, et al. Functional consequences of human induced pluripotent stem cell therapy: myocardial ATP turnover rate in the in vivo swine heart with postinfarction
remodeling [J]. Circulation, 2013, 127: 997-1008.
[31] Dai B, Huang W, Xu M, et al. Reduced collagen deposition in infarcted myocardium facilitates induced pluripotent stem cell engraftment and angiomyogenesis for improvement of left ventricular function [J]. Journal of the American College of Cardiology, 2011, 58: 2118-2127.
[32] Masumoto H, Ikuno T, Takeda M, et al. Human iPS cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration [J]. Scientific Reports, 2014, 4: 6716.
[33] Ye L, Chang Y H, Xiong Q, et al. Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells [J]. Cell Stem Cell, 2014, 15: 750-761.
[34] Sanchez-Freire V, Lee A S, Hu S,et al. Effect of human donor cell source on differentiation and function of cardiac induced pluripotent stem cells [J]. Journal of the American College of Cardiology, 2014, 64: 436-448.

[35] Birket M J, Mummery C L. Pluripotent stem cell derived cardiovascular progenitors—a developmental perspective [J]. Developmental Biology, 2015, 400: 169-179.
[36] Lundy S D, Zhu W Z, Regnier M, et al. Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells [J]. Stem Cells and Development, 2013, 22: 1991-2002.
[37] Andrews P W, Baker D, Benvinisty N, et al. Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: international stem cell banking
initiative (iscbi) [J]. Regenerative Medicine, 2015, 10: 1-44.